The “new paradigm” for OTC switches opening in the US with the Food and Drug Administration’s “additional conditions for nonprescription use” final rule published recently also brings new challenges for drug firms, the agency and the marketplace.
The rule’s requirement that formulations approved as additional conditions (ACNU) switches also remain available as Rx generics could limit the revenues for marketers of the nonprescription drugs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?